KRAS and neoplasm: The unexpected results indicate that (1) tumor cells with activated KRAS signatures were drug targets, but the KRAS mutation itself was not a target, and (2) the actual tumor population responsible for drug resistance might be masked by dominant genomic characteristics within a bulk population.